Second, these studies highlight the need to explore the vulnerabilities or synthetic lethality opportunities arising from these alterations, such as an increased dependency on BRD4 or the identification of ARID1B as a vulnerability in ARID1A-mutant cancers (123, 124). The gene discussed is ARID1A; the disease is cancer.